AI
| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Saturday, September 20, 2025 3:02:26 PM
Well, ex. If you continue a decade more, who knows?! At one point you might actually state something factually 👍
What SI 2025/87 actually does
Creates the world’s first statutory framework for decentralised/PoC manufacture with a Control Site (hub) that owns the licence and quality system for a network of hospital spokes, documented in a Decentralised Manufacturing Master File (DMMF). Onboarding new spokes occurs by updating that master file.
• How NWBO maps to that law
Sawston functions as the hub under Advent’s licences; spokes can be qualified hospital cleanrooms that run standardised steps under the hub’s QMS and release authority. This is a hub-and-spoke model, not cloning a full factory at each hospital.
• Role of Flaskworks EDEN
EDEN is a closed, automated system designed so production can move from Grade B to Grade C rooms, expanding capacity at materially lower facility cost and simpler operations - exactly the economics needed for safe decentralisation.
• Why PoC matters for DCVax-L
Autologous products depend on a patient’s tumour lysate + leukopak. Shortening “vein-to-vein” logistics reduces cold-chain risk and chain-of-identity complexity; a hub can still centralise testing/release while spokes run the automated step locally.
• What MHRA already signalled in 2024
A “de-risking cascade”:
1. Company concluded EDEN-made product is “substantially comparable.”
2. GMP licence granted for the automated process at Sawston.
3. MAA validated - the file, including CMC/comparability, accepted for full review.
These steps indicate the manufacturing approach cleared key gates.
• What NWBO actually says about scale-up
Filings describe:
Advent running Sawston; large cryostorage; release-testing streamlining; engineering for Grade C labs where EDEN may be deployed at lower cost and higher throughput. This is central to the company’s commercial plan.
• “Franchise” meaning, clarified
“Franchise” in NWBO materials means technology/IP leadership in dendritic-cell immunotherapy (platform + in-licensed portfolios), not retail-style franchising. (ASM remarks; 10-K IP section.)
Net: The law (SI 2025/87) empowers a hub-and-spoke PoC network; EDEN’s closed automation is built to make it economical and controllable in Grade C rooms; MHRA’s 2024 GMP licence and MAA validation show the model is already accepted for full review.
The board-post insinuations invert these facts.
How Linda Powers Testimony Shaped MHRA and NICE Reform
Flaskworks Eden 2.0: Building a Decentralized Point-Of-Care Network
What SI 2025/87 actually does
Creates the world’s first statutory framework for decentralised/PoC manufacture with a Control Site (hub) that owns the licence and quality system for a network of hospital spokes, documented in a Decentralised Manufacturing Master File (DMMF). Onboarding new spokes occurs by updating that master file.
• How NWBO maps to that law
Sawston functions as the hub under Advent’s licences; spokes can be qualified hospital cleanrooms that run standardised steps under the hub’s QMS and release authority. This is a hub-and-spoke model, not cloning a full factory at each hospital.
• Role of Flaskworks EDEN
EDEN is a closed, automated system designed so production can move from Grade B to Grade C rooms, expanding capacity at materially lower facility cost and simpler operations - exactly the economics needed for safe decentralisation.
• Why PoC matters for DCVax-L
Autologous products depend on a patient’s tumour lysate + leukopak. Shortening “vein-to-vein” logistics reduces cold-chain risk and chain-of-identity complexity; a hub can still centralise testing/release while spokes run the automated step locally.
• What MHRA already signalled in 2024
A “de-risking cascade”:
1. Company concluded EDEN-made product is “substantially comparable.”
2. GMP licence granted for the automated process at Sawston.
3. MAA validated - the file, including CMC/comparability, accepted for full review.
These steps indicate the manufacturing approach cleared key gates.
• What NWBO actually says about scale-up
Filings describe:
Advent running Sawston; large cryostorage; release-testing streamlining; engineering for Grade C labs where EDEN may be deployed at lower cost and higher throughput. This is central to the company’s commercial plan.
• “Franchise” meaning, clarified
“Franchise” in NWBO materials means technology/IP leadership in dendritic-cell immunotherapy (platform + in-licensed portfolios), not retail-style franchising. (ASM remarks; 10-K IP section.)
Net: The law (SI 2025/87) empowers a hub-and-spoke PoC network; EDEN’s closed automation is built to make it economical and controllable in Grade C rooms; MHRA’s 2024 GMP licence and MAA validation show the model is already accepted for full review.
The board-post insinuations invert these facts.
How Linda Powers Testimony Shaped MHRA and NICE Reform
Flaskworks Eden 2.0: Building a Decentralized Point-Of-Care Network
Bullish
